2016 NCRI Cancer Conference
6-9 November, Liverpool, UK
Tuesday News


Another fantastic day here at the 2016 NCRI Cancer Conference! Below you will find the latest news, highlights and photos from today.
NCRI2016: latest press releases
NCRI2016: Tuesday highlights from the NCRI bloggers

Multimodal genomics to improve precision oncology for prostate cancer: Embrace complexity!
Rob Bristow,  Ontario Cancer Institute/Princess Margaret Hospital, University of Toronto, Canada 

Prostate cancer treatment fails in almost 40% of cases, and in his talk, Rob Bristow explained the subgroup complexities of castration-resistant prostate cancer. Heterogeneity mutations, copy number alterations and methylation influence the aggressiveness of the cancer, and can potentially provide independent prognostic variables to predict metastatic disease. Increasing the precision of genomics, information on tumour microenvironment, sub-clonality and novel pathological indices will be valuable. 
There are many challenges with localised, non-indolent prostate cancer, but Rob encouraged everyone at the Conference to embrace the complexities, saying that biomarkers will provide information to allow subgrouping of patients so that tests can identify patients with poor prognosis and look for ways to treat them for better outcomes.

Targeting tumour evolvability

Reuben Harris,  from Howard Hughes Medical Institute, University of Minnesota, gave a plenary lecture entitled targeting tumour evolvability.

Reuben explained that cancers often display huge genetic heterogeneity and that tumour evolution is an ongoing process. He outlined some of the common sources of mutations, including in the anti-viral APOBEC enzymes, the focus of his talk.

His presentation highlighted recent progress in understanding in this area and he explained how the APOBEC enzymes are dominant drivers of tumour evolution and their inhibition is predicted to decrease tumour evolvability, therefore improving efficacy of existing targeted therapeutics.  

In the final part of his talk, Reuben shared some insights into the structure of the APOBEC enzymes. 

Improving the evidence base for symptom control in advanced cancer: Phase III studies of common interventions 
David Currow, Flinders University, Adelaide, Australia

David Currow's plenary talk painted a stark picture of failures to control symptoms in advanced bowel cancer patients. He explained there is a lack of evidence underpinning commonly used symptom control measures and more needs to be done to encourage researchers to find innovative new ways to treat pain and delirium. 
He presented data from 3 Phase III trials, demonstrating that common pain control measures can do more harm than good. He called for systematic and practical improvements in symptom control measures, and more willingness to involve patients with advanced cancers in clinical trials. To do this we need to bring clinical trials involvement in line with the normal care pathway, he said.

Proffered  paper sessions

This year's NCRI Cancer Conference includes 3 sessions of 'proffered papers' - abstracts highlighted by the Scientific Committee as important, and timely research carried out by prominent researchers.
Today we heard a series of fascinating talks from researchers reflecting the breadth of cancer research, from palliative care provision to metabolic pathways within tumours.
NCRI's Lorna Fern gave an animated insight into data collected over 10 years that indicates access to clinical trials for young people is in decline. She described a 5 point multi-stakeholder approach to improving access to research for young people with cancer to support improvements to access. Lorna is pursuing these through a programme of work supported by the Teenage Cancer Trust and facilitated by NCRI.

Tuesday photos

What's coming up on Wednesday

Mark your diaries! Check out some of the #NCRI2016 sessions on tomorrow:
  • Parallel session: Towards delivering truly personalised therapy for oesophageal cancerRoom 3A , 09.00-11.00
  • Parallel session: Cancer survivorship and late toxicity, Hall 1B, 09.00-11.00
  • NCRI Schools Event, Room 4, 09.30-14.30
  • Plenary lecture: Biology and biomarkers: Molecular correlates of clinical outcomes in patients with metastatic solid tumours treated with anti-PD-(L)1 agentsHall 1A, 12.00-12.40
  • Plenary lecture: Understanding responses to cancer therapy: The tissue is the issue but the scoop is in the poop, Hall 1A, 12.40-13.20

Download the NCRI Conference App

Download the NCRI Conference App to keep-up-to date with programme updates and the latest science. For any issues downloading the App, please contact the general enquiries desk.
  • Browse and search abstracts
  • Live Q&A during sessions
  • Make notes and email them to yourself
  • Network with other delegates
  • View the programme and learn more about sessions 
  • Win prizes daily by playing the Conference App Challenge
Download the App here:

Exhibition and the NCRI Meeting Point: Get the most out of NCRI2016!
  • Check out this year's list of exhibitors 
  • Get your free USB stick with abstracts from NCRI2016
  • Missed a session? Not to worry, we have you covered with NCRI Flix. Catch up on demand directly at the NCRI Meeting Point on the lower floor.
Useful information

Follow all the news and updates from NCRI2016 on Twitter and get involved by using the hashtag #NCRI2016 

Wifi access
Free_wifi - No password needed


Follow us on Twitter  View our profile on LinkedIn  View our videos on YouTube